Hydrocodone (Vicodin, Norco): Dependence, Withdrawal, and Recovery Support

Hydrocodone is the opioid in Vicodin, Norco, and Lortab, and for years it was the painkiller American medicine reached for first. When the DEA moved hydrocodone combination products into Schedule II in 2014, it wrote that "Hydrocodone is the most frequently prescribed opioid in the United States with nearly 137 million prescriptions for HCPs dispensed in 2013" (Federal Register, 2014). That is a lot of people who started with a wisdom tooth or a back strain and found, months later, that they could not skip a day. It is hard to stop because the tablet wears off in a few hours, because the acetaminophen beside it puts the liver at risk as the dose climbs, and because a pill bought outside a pharmacy today may be fentanyl. This page covers dependence, withdrawal, why the real danger comes after withdrawal rather than during it, treatment, drug testing, and how weekly support at home fits once a prescriber is involved.

What hydrocodone is and how it works

The DEA describes hydrocodone as "a semi-synthetic opioid most closely related to codeine in structure and morphine in producing opiatelike effects" (DEA, 2025). In the United States it is almost always sold in combination. Norco pairs it with acetaminophen in 5/325, 7.5/325, and 10/325 mg strengths and is approved "for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate" (Norco prescribing information). Vicodin and Lortab are the same combination under other names (DEA). Hysingla ER is single-ingredient hydrocodone in a once-daily tablet from 20 to 120 mg, approved only for "severe and persistent pain that requires an extended treatment period with a daily opioid analgesic" (Hysingla ER prescribing information, section 1).

The DEA's slang reference lists "Hydros," "Tabs," "Vics," "Vikes," "Watsons," and, tellingly, "Triple V (Vicodin taken with Valium and Vodka)" (DEA, 2018). Members also say "norcos."

Hydrocodone is a "full opioid agonist with relative selectivity for the mu-opioid receptor" (Norco, Clinical Pharmacology), the receptor behind the pain relief, the warmth, and the slowed breathing. The liver clears it through two enzymes, CYP3A4 and CYP2D6, and the second one turns a small share of it into hydromorphone (Norco, Clinical Pharmacology). One of those facts matters for drug interactions and the other for drug tests. It is short-acting: in the combination tablet "the half-life was determined to be 3.8 ± 0.3 hours" (Norco, Clinical Pharmacology), so a dependent body notices the gap the same afternoon. Hysingla ER stretches that out, with a median time to peak of 14 to 16 hours and a terminal half-life "ranging from 7 to 9 hours" (Hysingla ER, section 12.3). Its tablet is built to resist crushing, but the label concedes that "abuse of HYSINGLA ER by the intravenous, intranasal, and oral routes is still possible" (Hysingla ER, section 9.2).

For decades the combination products sat in Schedule III, defined by the DEA as "drugs with a moderate to low potential for physical and psychological dependence" (DEA drug scheduling). That ended on October 6, 2014, when the DEA moved them to Schedule II after finding that "HCPs are widely diverted and abused at rates largely similar to that of oxycodone products" (Federal Register, 2014). Prescribing has fallen since, from a peak of about 144.5 million hydrocodone prescriptions in 2011 to 47.4 million in 2024, yet 3.4 million people aged 12 and older still reported misusing a hydrocodone product in the past year in 2024 (DEA, 2025).

The pill in the baggie is the newer problem. The DEA reports that "Many fake pills are made to look like prescription opioids such as oxycodone (Oxycontin, Percocet), hydrocodone (Vicodin), and alprazolam (Xanax)," and that lab testing finds "7 out of every 10 pills with fentanyl contain a potentially lethal dose" (DEA, September 2023). The agency seized "more than 47 million fentanyl-laced counterfeit pills" in 2025 (DEA, One Pill Can Kill). If the "norcos" come from a phone rather than a pharmacy, assume fentanyl.

Dependence, misuse, and addiction are not the same thing

People blur these words, and the blur produces shame that helps nobody. The label separates them. "Physical dependence is a physiological state in which the body adapts to the drug after a period of regular exposure, resulting in withdrawal symptoms after abrupt discontinuation or a significant dosage reduction of a drug" (Norco, Drug Abuse and Dependence). Dependence happens to the nurse who took Norco exactly as directed after a shoulder repair. It is pharmacology, and it is expected.

Misuse is taking it in a way it was not prescribed: two instead of one, earlier than the bottle allows, or from someone else's supply. Addiction, in clinical language an opioid use disorder, is continuing despite harm: the early refill that becomes a second prescriber, the leftover pills from a relative, and a day that reorganizes itself around the next tablet. The label is plain that the dose does not settle the question: "Addiction can occur at recommended dosages and if the drug is misused or abused" (Norco, Warnings). A person can be dependent without being addicted, and addicted at three tablets a day. What we ask families is what the pill has started to cost.

Signs hydrocodone has become a problem

Here is what families describe to us most often. The thirty-day prescription is gone by day twenty, and there is always a reason. There is a low, sweaty, irritable stretch before the next dose and a visible lift after it. Someone is hiding the bottle, or borrowing from a parent's cabinet. Naps look more like nodding, and a partner notices "cold and clammy skin, constricted pupils" and breathing that seems too slow, which the label lists among the signs of too much (Norco, Overdosage). Drinking alongside the pills has become routine; the DEA notes hydrocodone "is generally abused orally, often in combination with alcohol" (DEA, 2025). The pills now arrive in a baggie. Any one of these is worth a conversation. Several together are worth a call.

Why stopping hydrocodone is rarely the dangerous part

Opioid withdrawal is miserable and almost never fatal. The WHO's withdrawal management guideline says it "can feel like a very bad flu," and that "opioid withdrawal is not usually life-threatening" (WHO, 2009). Alcohol and benzodiazepine withdrawal can kill. Hydrocodone withdrawal, on its own, is not in that category.

The danger sits in two other places. The first is stopping abruptly when pain and dependence are both real. The label instructs, "Do not abruptly discontinue NORCO in a patient physically dependent on opioids," because "Rapid discontinuation of opioid analgesics in patients who are physically dependent on opioids has resulted in serious withdrawal symptoms, uncontrolled pain, and suicide" (Norco, Dosage and Administration).

The second is the one that fills obituaries. Tolerance falls within days of stopping, and last month's ordinary dose can stop a person's breathing. The WHO guideline advises that everyone who has withdrawn from opioids be told they "are at increased risk of overdose due to reduced opioid tolerance" (WHO). SAMHSA's overdose toolkit lists "using drugs after a recent period of abstinence, which may decrease previous tolerance levels" among the leading risk factors, alongside leaving jail or a treatment setting without medication for opioid use disorder (SAMHSA, 2023). Add the chance that today's "Vicodin" is a fentanyl press, and you have the reason we treat the weeks after withdrawal as the highest-risk stretch rather than the finish line.

Hydrocodone withdrawal timeline

The label's list of withdrawal signs starts with "restlessness, lacrimation, rhinorrhea, yawning, perspiration, chills, myalgia, mydriasis" and runs through irritability, anxiety, backache, joint pain, cramps, insomnia, nausea, vomiting, diarrhea, and a raised pulse and blood pressure (Norco, Drug Abuse and Dependence). For short-acting opioids the WHO gives the shape as onset 8 to 24 hours after last use and duration of 4 to 10 days (WHO, 2009). Everyone is different; treat this as the general shape.

First 8 to 24 hours

With a half-life under four hours, Norco leaves quickly, and the first signs usually arrive before the next day: yawning, a runny nose, watery eyes, sweating, goosebumps, anxiety, and a restless sense that something is wrong. People on Hysingla ER, with its slower release, may not feel much until the second day.

Days 2 to 4

This is the peak: deep muscle and bone aches, stomach cramps, diarrhea, vomiting, alternating chills and sweats, restless legs, and nights without sleep. Dehydration is the one physical complication worth watching; the WHO guideline recommends 2 to 3 liters of fluid a day (WHO). This is also where "just one to sleep" happens, which is why a plan for these exact nights matters more than resolve.

Days 5 to 10

The physical symptoms fade for most people. Appetite and sleep are still off, and cravings attach to the situations hydrocodone used to handle: the end of a shift, a pain flare, the hour after the kids are in bed.

Weeks 2 and beyond

Low mood, anxiety, poor sleep, and a flatness that makes everything feel like effort can hang on for weeks. This is where people quietly return to use, and where lost tolerance makes that return most dangerous.

How treatment works

For someone physically dependent on a prescribed dose, the label's instruction is a slow taper: "initiate the taper by a small enough increment (e.g., no greater than 10% to 25% of the total daily dose) to avoid withdrawal symptoms, and proceed with dose-lowering at an interval of every 2 to 4 weeks" (Norco, Dosage and Administration). For someone on six Norco 10/325 a day, the first step down is between half a tablet and a tablet and a half, and the whole thing runs months. That pace is the point.

For someone whose use has become an opioid use disorder, the standard of care is medication. SAMHSA's TIP 63 covers the three FDA-approved options, methadone, buprenorphine, and naltrexone, and states that they reduce illicit opioid use, keep people in treatment, and lower the risk of overdose death compared with placebo or no medication (SAMHSA TIP 63, Part 1). It is blunt about detox alone: "most patients with OUD who undergo medically supervised withdrawal will start using opioids again," and "arbitrary time limits on the duration of treatment with OUD medication are inadvisable." The ASAM guideline agrees: "There is no recommended time limit for pharmacological treatment" (ASAM, 2020).

Naloxone belongs in every house where hydrocodone is. The Hysingla ER label tells prescribers to "Discuss the availability of naloxone for the emergency treatment of opioid overdose with the patient and caregiver" (Hysingla ER, section 2.2). Narcan 4 mg nasal spray has been sold without a prescription since the FDA approved over-the-counter use on March 29, 2023 (FDA). Buy two.

Hydrocodone with alcohol, benzodiazepines, or other drugs

The boxed warning states that "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death" (Norco boxed warning). The DEA's "Triple V," Vicodin with Valium and vodka, is that sentence rendered as a Friday night.

Two interactions are specific to hydrocodone. Because CYP3A4 clears it, anything that blocks that enzyme raises the blood level. The label warns that "Concomitant use of NORCO Tablets with a CYP3A4 inhibitor, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir), may increase plasma concentrations" and "may cause potentially fatal respiratory depression" (Norco, Warnings). An antibiotic for a sinus infection is the kind of thing nobody thinks to mention.

The other is acetaminophen. In January 2011 the FDA asked manufacturers to "limit the amount of acetaminophen in these products to 325 mg per tablet, capsule, or other dosage unit" and to add "a Boxed Warning highlighting the potential for severe liver injury" (FDA, 2011). The Norco boxed warning now reads: "Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4,000 milligrams per day, and often involve more than one acetaminophen-containing product" (Norco boxed warning). The label caps Norco 10/325 at six tablets a day. Twelve of them is 3,900 mg of acetaminophen before a single Tylenol, which is why someone whose dose has climbed needs a liver panel, not a lecture.

The national picture has improved. Drug overdose deaths fell from 105,007 in 2023 to 79,384 in 2024, a 26.2 percent drop, and the death rate involving natural and semisynthetic opioids, the CDC category that includes hydrocodone, fell 20.7 percent, from 2.9 to 2.3 per 100,000 (CDC NCHS Data Brief 549, 2026). Hydrocodone is still on the CDC's short list of drugs most often involved in prescription opioid overdose deaths (CDC, 2025).

Drug testing for hydrocodone

The standard "opiates" line on most panels is not built for it. The American College of Medical Toxicology explains that "Most clinical immunoassays for opiates have morphine and codeine as their target analytes," and that "Separate assays are required to reliably detect buprenorphine, fentanyl, fentanyl analogs, hydrocodone, methadone," and the other semisynthetic and synthetic opioids (ACMT, 2021). A negative opiate result from a workplace panel says nothing about hydrocodone. And because the body converts a little hydrocodone to hydromorphone, a lab report that shows both is usually one drug, not two.

Saliva data come mostly from single doses in healthy volunteers. In one controlled study, 12 adults took a single 20 mg dose of hydrocodone bitartrate, and at a 1 ng/mL cutoff the mean detection time in oral fluid was 30 hours for hydrocodone and 18 hours for its metabolite norhydrocodone (Cone et al., J Anal Toxicol, 2015). Daily use at higher doses extends that, and the lab's cutoff moves it, so we would rather not quote one number for everyone. A prescribed, tapering dose will test positive; what matters is whether the result matches the plan.

Our members use saliva-based screening that is assigned at random through the week. Hydrocodone is not a separate line on the instant 10-panel strip, and the strip's opiate line does not reliably catch it, so a member whose plan involves hydrocodone has their screening run as the lab-confirmed oral fluid test, which reports hydrocodone and hydromorphone individually at a 2 ng/mL cutoff with LC-MS/MS confirmation. You do not choose whether you test; you choose who sees the results. For most members that means the prescriber and, if they want, a spouse or parent. We explain the details in our guide to how sobriety monitoring works.

How recovery from hydrocodone works with Accountable

We are not a detox and we do not prescribe. The taper or the buprenorphine belongs to your doctor. What we provide is the support around it, at home, for as long as you need it.

1. Get the full picture

In the first sessions your coach maps what is actually going on: which product, how many a day, for how long, whether the pills come from a pharmacy or a phone, and whether alcohol, a benzodiazepine, extra acetaminophen, or untreated pain is part of the picture. If there is no prescriber managing a taper or medication for opioid use disorder yet, we help you find one, and with your permission we coordinate so everyone works from the same plan.

2. Build a plan that fits your life

A plan that only works if you take a month off is a plan you will abandon. Your coach helps you plan around the real calendar: what you will do when the back pain flares, which evenings the cravings run hottest, who you will text before you text the cousin who still has a prescription. Daily peer group meetings and a weekly family Zoom group give the people around you their own place to get support.

3. Weekly check-ins through the long stretch

The flat, restless weeks after hydrocodone are where people quietly give up, and where a return to the old dose is most likely to be fatal. Your coach shows up every week, and the saliva screening turns "I think she's doing okay" into a shared record that you control. When a slip happens, we treat it as information: the plan changes, the support goes up, and we check that the naloxone is still in the drawer. Every coach at Accountable has their own recovery behind them, and many started, as you may have, with a prescription.

Accountable is covered by a growing list of commercial health plans, with more added each month, and private-pay plans start at $375 per month. You can check your coverage in a few minutes or call the care team at (646) 450-7641. Families are welcome to make the first call; see our page for families.

Common questions

How long does hydrocodone stay in your system?

The half-life of hydrocodone in a combination tablet like Norco is about 3.8 hours (Norco, Clinical Pharmacology), so most of a single dose is gone within a day; Hysingla ER's half-life is 7 to 9 hours (Hysingla ER, section 12.3). In saliva, one controlled study found a mean detection time of 30 hours after a single 20 mg dose (Cone et al., 2015). Regular use extends detection, and urine windows are longer.

How long does hydrocodone withdrawal last?

For short-acting opioids the WHO puts onset at 8 to 24 hours after the last dose and duration at 4 to 10 days (WHO, 2009). Sleep, mood, and cravings can take weeks longer. A taper of 10 to 25 percent every two to four weeks keeps most of this mild (Norco, Dosage and Administration).

Is Vicodin the same as Norco?

Both are hydrocodone with acetaminophen, and both have been Schedule II since October 6, 2014 (Federal Register, 2014). Norco comes in 5, 7.5, and 10 mg of hydrocodone with 325 mg of acetaminophen, the ceiling the FDA asked for in 2011 (FDA, 2011).

Does hydrocodone show up on a drug test?

Not reliably on a standard opiate screen, which targets morphine and codeine; hydrocodone needs its own assay (ACMT, 2021). A lab-confirmed test reports it directly, and a prescribed dose will test positive.

What should I do if someone on hydrocodone will not wake up?

Call 911, give naloxone, and give rescue breaths if they are not breathing; otherwise put them on their side. SAMHSA's toolkit says "Naloxone and nalmefene do not cause harm if given to a person who is not experiencing opioid overdose" (SAMHSA, 2023). Naloxone "rapidly reverses the effects of opioid overdose" (FDA), but it can wear off before a once-daily tablet like Hysingla ER does, so they still need emergency care.

Sources

• U.S. Food and Drug Administration. Norco (hydrocodone bitartrate and acetaminophen tablets, USP) CII, prescribing information, 2019.

• U.S. Food and Drug Administration. Hysingla ER (hydrocodone bitartrate) extended-release tablets, prescribing information, revised December 2023.

• U.S. Food and Drug Administration. Hysingla ER (hydrocodone bitartrate) extended-release tablets, prescribing information, revised December 2016 (section 12.3, pharmacokinetics).

• U.S. Food and Drug Administration. FDA Drug Safety Communication: Prescription Acetaminophen Products to be Limited to 325 mg Per Dosage Unit; Boxed Warning Will Highlight Potential for Severe Liver Failure. January 13, 2011.

• U.S. Food and Drug Administration. FDA Approves First Over-the-Counter Naloxone Nasal Spray. Press announcement, March 29, 2023.

• Drug Enforcement Administration. Schedules of Controlled Substances: Rescheduling of Hydrocodone Combination Products From Schedule III to Schedule II. Federal Register, final rule, August 22, 2014 (effective October 6, 2014).

• Drug Enforcement Administration, Diversion Control Division. Hydrocodone, drug and chemical information sheet, August 2025.

• Drug Enforcement Administration, Houston Division. Slang Terms and Code Words: A Reference for Law Enforcement Personnel. DEA-HOU-DIR-022-18, July 2018.

• Drug Enforcement Administration. Drug Scheduling.

• Drug Enforcement Administration. Fake Prescription Pills: Widely Available, Increasingly Lethal, One Pill Can Kill fact sheet, September 2023.

• Drug Enforcement Administration. One Pill Can Kill.

• Centers for Disease Control and Prevention, National Center for Health Statistics. Garnett MF, Miniño AM. Drug Overdose Deaths in the United States, 2023-2024. NCHS Data Brief No. 549, January 2026.

• Centers for Disease Control and Prevention. Prescription Opioids. Overdose Prevention, last reviewed June 10, 2025.

• World Health Organization. Clinical Guidelines for Withdrawal Management and Treatment of Drug Dependence in Closed Settings, chapter 4: Withdrawal Management. 2009, NCBI Bookshelf.

• Substance Abuse and Mental Health Services Administration. TIP 63: Medications for Opioid Use Disorder, Part 1: Introduction to Medications for Opioid Use Disorder Treatment. 2021 update, NCBI Bookshelf.

• Substance Abuse and Mental Health Services Administration. Overdose Prevention and Response Toolkit. PEP23-03-00-001, 2023.

• American Society of Addiction Medicine. Executive Summary of the Focused Update of the ASAM National Practice Guideline for the Treatment of Opioid Use Disorder. 2020.

• Stolbach AI, Connors NJ, Nelson LS, Kulig K. ACMT Practice Statement: Interpretation of Urine Opiate and Opioid Tests. American College of Medical Toxicology, September 13, 2021.

• Cone EJ, DePriest AZ, Heltsley R, Black DL, Mitchell JM, LoDico C, Flegel R. Prescription Opioids. IV: Disposition of Hydrocodone in Oral Fluid and Blood Following Single-Dose Administration. Journal of Analytical Toxicology. 2015;39(7):510-518.